In the present study, we have observed enhanced apoptosis when CHK1 inhibitors are combined with CPX-351 in TP53 mutant (THP.1) and TP53 null (U937, HL-60) AML lines in vitro, consistent with these earlier results. The gene discussed is TP53; the disease is acute myeloid leukemia.